Información del artículo
Las infecciones son la causa más importante de morbimortalidad en los pacientes trasplantados. Aparecen en tres momentos diferentes tras el trasplante dependiendo de factores quirúrgicos, el nivel de inmunosupresión, la exposición ambiental y el tipo de profilaxis utilizada. Las infecciones bacterianas surgen sobre todo en los primeros 2 meses y pueden hacerlo como bacteriemia, infección de la herida quirúrgica, infección intraabdominal o neumonía. La tuberculosis en el paciente trasplantado tiene una presentación más agresiva que en el paciente inmunocompetente y además su manejo se ve dificultado por la interacción farmacológica entre los fármacos tuberculostáticos y los inmunosupresores. Los virus producen infección de manera directa en estos pacientes pero además algunos de ellos, el citomegalovirus y el herpesvirus humano 6, son inmunomoduladores y pueden facilitar otras infecciones y el rechazo del injerto. El uso de técnicas de reacción en cadena de la polimerasa y antigenemia ha hecho posible un diagnóstico más precoz de la infección por citomegalovirus y la implantación de medidas profilácticas. Las infecciones fúngicas siguen presentando una alta mortalidad a pesar de las nuevas técnicas diagnósticas y los nuevos fármacos antifúngicos.
Palabras clave:
Trasplante hepático
Infección fúngica profunda
Citomegalovirus
Infection is the main cause of morbidity and mortality in liver transplant patients. Infections appear in three different periods following transplantation and are related to surgical factors, the degree of immunosuppression, environmental exposure and the type of prophylaxis used. Bacterial infections occur in the first two months after transplantation as bacteremia, surgical wound and intra-abdominal infection, or pneumonia. Tuberculosis in the liver transplant recipient is more aggressive than in immunocompetent persons. Viruses produce direct infection in these patients; moreover, some viruses (e.g., cytomegalovirus and human herpes virus 6) are immunomodulators and can facilitate other infections and graft rejection. Polymerase chain reaction and antigenemia techniques have made possible prompt diagnosis of cytomegalovirus infection and the implementation of prophylactic strategies. Fungal infections still have a high associated mortality rate, despite new diagnostic techniques and new antifungal drugs.
Key words:
Liver transplant
Deep fungal infection
Cytomegalovirus
El Texto completo está disponible en PDF
Bibliografía
[1.]
J.E. Blair, S. Kusne.
Bacterial, mycobacterial, and protozoal infections after liver transplantation – part I.
Liver Transpl, 11 (2005), pp. 1452-1459
[2.]
D.L. George, P.M. Arnow, A.S. Fox, A.L. Baker, J.R. Thistlethwaite, J.C. Emond, et al.
Bacterial infection as a complication of liver transplantation: epidemiology and risk factors.
Rev Infect Dis, 13 (1991), pp. 387-396
[3.]
K. Itoh, T. Hashimoto, Y. Shimizu, Y. Otobe, M. Tanaka, Y. Nakamura, et al.
Bacterial and fungal infections after living related donor liver transplantation.
Transplant Proc, 28 (1996), pp. 2404-2405
[4.]
N. Singh, D.L. Paterson, T. Gayowski, M.M. Wagener, I.R. Marino.
Predicting bacteremia and bacteremic mortality in liver transplant recipients.
Liver Transpl, 6 (2000), pp. 54-61
[5.]
C.S. Hollenbeak, E.J. Alfrey, W.W. Souba.
The effect of surgical site infections on outcomes and resource utilization after liver transplantation.
Surgery, 130 (2001), pp. 388-395
[6.]
O.A. Tachopoulou, D.P. Vogt, J.M. Henderson, M. Baker, T.F. Keys.
Hepatic abscess after liver transplantation: 1990-2000.
Transplantation, 75 (2003), pp. 79-83
[7.]
F.G. Durán, B. Piqueras, M. Romero, J.A. Carneros, A. De Diego, M. Salcedo, et al.
Pulmonary complications following orthotopic liver transplant.
Transpl Int, 11 (1998), pp. 255-259
[8.]
N. Singh, D.L. Paterson, F.Y. Chang, T. Gayowski, C. Squier, M.M. Wagener, et al.
Methicillin-resistant Staphylococcus aureus: the other emerging resistant gram-positive coccus among liver transplant recipients.
Clin Infect Dis, 30 (2000), pp. 322-327
[9.]
D.L. Paterson, J.D. Rihs, C. Squier, T. Gayowski, A. Sagnimeni, N. Singh.
Lack of efficacy of mupirocin in the prevention of infections with Staphylococcus aureus in liver transplant recipients and candidates.
Transplantation, 75 (2003), pp. 194-198
[10.]
S.A. McNeil, P.N. Malani, C.E. Chenoweth, R.J. Fontana, J.C. Magee, J.D. Punch, et al.
Vancomycin-resistant enterococcal colonization and infection in liver transplant candidates and recipients: a prospective surveillance study.
Clin Infect Dis, 42 (2006), pp. 195-203
[11.]
N. Benito, O. Sued, A. Moreno, J.P. Horcajada, J. González, M. Navasa, et al.
Diagnosis and treatment of latent tuberculosis infection in liver transplant recipients in an endemic area.
Transplantation, 74 (2002), pp. 1381-1386
[12.]
S. Kusne, J.E. Blair.
Viral and fungal infections after liver transplantation – part II.
Liver Transpl, 12 (2006), pp. 2-11
[13.]
D.H. Dockrell, J. Prada, M.F. Jones, R. Patel, A.D. Badley, W.S. Harmsen, et al.
Seroconversion to human herpesvirus 6 following liver transplantation is a marker of cytomegalovirus disease.
J Infect Dis, 176 (1997), pp. 1135-1140
[14.]
R. Teixeira, S. Pastacaldi, S. Davies, A.P. Dhillon, V.C. Emery, K. Rolles, et al.
The influence of cytomegalovirus viraemia on the outcome of recurrent hepatitis C after liver transplantation.
Transplantation, 70 (2000), pp. 1454-1458
[15.]
A. Gaeta, C. Nazzari, S. Angeletti, M. Lazzarini, E. Mazzei, C. Mancini.
Monitoring for cytomegalovirus infection in organ transplant recipients: analysis of pp65 antigen, DNA and late mRNA in peripheral blood leukocytes.
J Med Virol, 53 (1997), pp. 189-195
[16.]
M.A. Moreno.
Viral infections in solid organ transplant recipients.
Enferm Infecc Microbiol Clin, 15 (1997), pp. 22-33
[18.]
A.P. Limaye.
Ganciclovir-resistant cytomegalovirus in organ transplant recipients.
Clin Infect Dis, 35 (2002), pp. 866-872
[19.]
J.M. Morales, M.A. Muñoz, G. Fernández Zatarain, C. García Cantón, M.A. García Rubiales, A. Andrés, et al.
Reversible acute renal failure caused by the combined use of foscarnet and cyclosporin in organ transplanted patients.
Nephrol Dial Transplant, 10 (1995), pp. 882-883
[20.]
J. De Otero, J. Gavalda, E. Murio, V. Vargas, I. Calico, L. Llopart, et al.
Cytomegalovirus disease as a risk factor for graft loss and death after orthotopic liver transplantation.
Clin Infect Dis, 26 (1998), pp. 865-870
[21.]
R.H. Rubin.
Preemptive therapy in immunocompromised hosts.
N Engl J Med, 324 (1991), pp. 1057-1059
[22.]
E. Gane, F. Saliba, G.J. Valdecasas, J. O’Grady, M.D. Pescovitz, S. Lyman, et al.
Randomized trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected].
Lancet, 350 (1997), pp. 1729-1733
[23.]
C. Paya, A. Humar, E. Domínguez, K. Washburn, E. Blumberg, B. Alexander, et al.
Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients.
Am J Transplant, 4 (2004), pp. 611-620
[24.]
C. Díaz-Pedroche, C. Lumbreras, P. Del Valle, R. San Juan, S. Hernando, D. Folgueira, et al.
Efficacy and safety of valgancyclovir as preemptive therapy for the prevention of cytomegalovirus disease in solid organ transplant recipients.
Transplant Proc, 37 (2005), pp. 3766-3767
[25.]
J.M. Park, K.D. Lake, J.D. Arenas, R.J. Fontana.
Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients.
Liver Transpl, 12 (2006), pp. 112-116
[26.]
N. Singh, C. Wannstedt, L. Keyes, T. Gayowski, M.M. Wagener, T.V. Cacciarelli.
Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease.
Transplantation, 79 (2005), pp. 85-90
[27.]
D.R. Snydman.
Historical overview of the use of cytomegalovirus hyperimmune globulin in organ transplantation.
Transpl Infect Dis, 3 (2001), pp. 6-13
[28.]
D.R. Snydman, M.E. Falagas, R. Avery, C. Perlino, R. Ruthazer, R. Freeman, et al.
Use of combination cytomegalovirus immune globulin plus ganciclovir for prophylaxis in CMV-seronegative liver transplant recipients of a CMV-seropositive donor organ: a multicenter, open-label study.
Transplant Proc, 33 (2001), pp. 2571-2575
[29.]
A.D. Pinna, J. Rakela, A.J. Demetris, J.J. Fung.
Five cases of fulminant hepatitis due to herpes simplex virus in adults.
Dig Dis Sci, 47 (2002), pp. 750-754
[30.]
J.A. Fishman, R.H. Rubin.
Infection in organ-transplant recipients.
N Engl J Med, 338 (1998), pp. 1741-1751
[31.]
R. Cirelli, K. Herne, M. McCrary, P. Lee, S.K. Tyring.
Famciclovir: review of clinical efficacy and safety.
Antiviral Res, 29 (1996), pp. 141-151
[32.]
S.K. Tyring, D. Baker, W. Snowden.
Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years’ experience with acyclovir.
J Infect Dis, 186 (2002), pp. 40-46
[33.]
A. Jain, M. Nalesnik, J. Reyes, R. Pokharna, G. Mazariegos, M. Green, et al.
Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience.
Ann Surg, 236 (2002), pp. 429-436
[34.]
G. Dotti, R. Fiocchi, T. Motta, C. Mammana, E. Gotti, S. Riva, et al.
Lymphomas occurring late after solid-organ transplantation: influence of treatment on the clinical outcome.
Transplantation, 74 (2002), pp. 1095-1102
[35.]
T.E. Starzl, M.A. Nalesnik, K.A. Porter, M. Ho, S. Iwatsuki, B.P. Griffith, et al.
Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy.
Lancet, 1 (1984), pp. 583-587
[36.]
E.A. Verschuuren, S.J. Stevens, G.W. Van Imhoff, J.M. Middeldorp, C. De Boer, G. Koeter, et al.
Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication.
Transplantation, 73 (2002), pp. 100-104
[37.]
R.R. Razonable, C.V. Paya.
The impact of human herpesvirus-6 and -7 infection on the outcome of liver transplantation.
Liver Transpl, 8 (2002), pp. 651-658
[38.]
A. Humar, D. Kumar, J. Raboud, A.M. Caliendo, G. Moussa, G. Levy, et al.
Interactions between cytomegalovirus, human herpesvirus-6, and the recurrence of hepatitis C after liver transplantation.
Am J Transplant, 2 (2002), pp. 461-466
[39.]
Z. Kadry, O. Bronsther, J.J. Fung.
Kaposi's sarcoma in liver transplant recipients on FK506.
Transplantation, 65 (1998), pp. 1140
[40.]
M.E. Roland, P.G. Stock.
Liver transplantation in HIV-infected recipients.
Semin Liver Dis, 26 (2006), pp. 273-284
[41.]
J. Fortún, P. Martín-Dávila, M.E. Álvarez, A. Sánchez-Sousa, C. Quereda, E. Navas, et al.
Aspergillus antigenemia sandwich-enzyme immunoassay test as a serodiagnostic method for invasive aspergillosis in liver transplant recipients.
Transplantation, 71 (2001), pp. 145-149
[42.]
J. Fortún, P. Martín-Dávila, S. Moreno, E. De Vicente, J. Nuño, A. Candelas, et al.
Risk factors for invasive aspergillosis in liver transplant recipients.
Liver Transpl, 8 (2002), pp. 1065-1070
[43.]
T.J. Walsh, J.W. Hiemenz, N.L. Seibel, J.R. Perfect, G. Horwith, L. Lee, et al.
Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases.
Clin Infect Dis, 26 (1998), pp. 1383-1396
[44.]
R. Herbrecht, D.W. Denning, T.F. Patterson, J.E. Bennett, R.E. Greene, J.W. Oestmann, et al.
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
N Engl J Med, 347 (2002), pp. 408-415
[45.]
S.A. Pacetti, S.P. Gelone.
Caspofungin acetate for treatment of invasive fungal infections.
Ann Pharmacother, 37 (2003), pp. 90-98
[46.]
D.J. Winston, R.W. Busuttil.
Randomized controlled trial of oral itraconazole solution versus intravenous/oral fluconazole for prevention of fungal infections in liver transplant recipients.
Transplantation, 74 (2002), pp. 688-695
[47.]
J. Fortún, P. Martín-Dávila, S. Moreno, R. Bárcena, E. De Vicente, A. Honrubia, et al.
Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of amphotericin B in high-risk patients.
J Antimicrob Chemother, 52 (2003), pp. 813-819
[48.]
T. Shah, W.K. Lai, P. Gow, J. Leeming, D. Mutimer.
Low-dose amphotericin for prevention of serious fungal infection following liver transplantation.
Transpl Infect Dis, 7 (2005), pp. 126-132
[49.]
J.M. Aguado, J.A. Herrero, J. Gavalda, J. Torre-Cisneros, M. Blanes, G. Rufi, et al.
Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Spanish Transplantation Infection Study Group, GESITRA.
Transplantation, 63 (1997), pp. 1278-1286
[50.]
N. Singh, D.L. Paterson.
Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management.
Clin Infect Dis, 27 (1998), pp. 1266-1277
[51.]
J. Hernández-Pérez, M. Yebra-Bango, E. Jiménez-Martínez, C. Sanz-Moreno, V. Cuervas-Mons, L. Alonso Pulpon, et al.
Visceral leishmaniasis (kala-azar) in solid organ transplantation: report of five cases and review.
Clin Infect Dis, 29 (1999), pp. 918-921
[52.]
L. Chiche, A. Lesage, C. Duhamel, E. Salame, M. Malet, D. Samba, et al.
Posttransplant malaria: first case of transmission of Plasmodium falciparum from a white multiorgan donor to four recipients.
Transplantation, 75 (2003), pp. 166-168
[53.]
C.P. Wajszczuk, J.S. Dummer, M. Ho, D.H. Van Thiel, T.E. Starzl, S. Iwatsuki, et al.
Fungal infections in liver transplant recipients.
Transplantation, 40 (1985), pp. 347-353
[54.]
S. Kusne, J.S. Dummer, N. Singh, S. Iwatsuki, L. Makowka, C. Esquivel, et al.
Infections after liver transplantation: an analysis of 101 consecutive cases.
Medicine (Baltimore), 67 (1988), pp. 132-143
[55.]
J.J. Wade, N. Rolando, K. Hayllar, J. Philipott-Howard, M.W. Casewell, R. Williams.
Bacterial and fungal infections after liver transplantation. An analysis of 284 patients.
Hepatology, 21 (1995), pp. 1328-1336
[56.]
J. Briegel, H. Forst, B. Spill, A. Haas, B. Grabein, M. Haller, et al.
Risk factors for systemic fungal infections in liver transplant recipients.
Eur J Clin Microbiol Infect Dis, 14 (1995), pp. 375-382
[57.]
R. Patel, D. Portela, A.D. Badley, W.S. Harmsen, J.J. Larson-Keller, D.M. Ilstrup, et al.
Risk factors of invasive Candida and non-Candida fungal infections after liver transplantation.
Transplantation, 62 (1996), pp. 926-934
[58.]
M. Miguélez, C. Lumbreras, J.A. Herrero, J.M. Aguado, A. Del Palacio, F. Colina, et al.
Infección fúngica profunda en receptores de un trasplante de hígado: análisis de 21 casos.
Med Clin (Barc), 110 (1998), pp. 406-410
[59.]
N. Singh, M.M. Wagener, I.R. Marino, T. Gayowski.
Trands in invasive fungal infections in liver transplant recipients: correlation with evolution in transplantation practices.
Transplantation, 73 (2002), pp. 63-67
[60.]
N. Singh, L. Mieles, V.L. Yu, T. Gayowski.
Invasive aspergillosis in liver transplant recipients: association with candidemia and consumption coagulopathy and failure with low-dose amphotericin B.
Clin Infect Dis, 17 (1993), pp. 906-908
[61.]
J. Tollemar, K. Hockerstedt, B.G. Ericzon, H. Jalanko, O. Ringden.
Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients.
Transplantation, 59 (1995), pp. 45-50
[62.]
C. Lumbreras, V. Cuervas-Mons, P. Jara, A. Del Palacio, V.S. Turrión, C. Barrios, et al.
Randomized trail of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation.
J Infect Dis, 174 (1996), pp. 583-588
[63.]
D.J. Winston, A. Pakrasi, R.W. busuttil.
Prophylactic fluconazole in liver trasplant recipients. A randomized, double-blind, placebo-controlled trial.
Ann Intern Med, 131 (1999), pp. 729-737
[64.]
D.J. Winston, R.W. Busuttil.
Randomized controlled trial of oral itraconazole solution versus intravenous/oral fluconazole for prevention of fungal infections in liver transplant recipients.
Transplantation, 74 (2002), pp. 688-695
Copyright © 2007. Elsevier España S.L.. Todos los derechos reservados
